Abstract
The paper considers the specifics of innovation activity and scientific and technological development in R&D intensive pharmaceutical industry. A generalized comparison of Russian and foreign pharmaceutical industry during the current COVID-19 pandemic is carried out. The dynamics of the domestic pharmaceutical market development is analyzed; the trends and persisting problems are studied. The potential of growth of domestic pharmaceutical industry with adequate interaction of state and business in entering the world markets was shown. It is pointed out that both abroad and in Russia during the pandemic the industry became one of the few where research costs had increased significantly. The paper shows that support policy for pharmaceutical industry in Russia over the next 10 years will be emphasized on the creation of own innovative drugs (including biotech types), and generics for the domestic market. The new ways of production and digitalization of the pharmaceutical industry remain outside the current support measures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
